RCAG
ATRA icon

Rehmann Capital Advisory Group’s Atara Biotherapeutics ATRA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed -$1.36K – 2134
2018
Q2 		$1.36K Buy
+1
New +$1.07K ﹤0.01% 1898
2018
Q1 		– Hold
0
– – – 2003

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Eagle Asset Management
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Rehmann Capital Advisory Group's ATRA Position: Q3 2018 in Review

Rehmann Capital Advisory Group sold out of Atara Biotherapeutics (ATRA) in Q3 2018, closing a stake of 1 share — an estimated $1.36K sold.

Rehmann Capital Advisory Group first reported a position in ATRA in Q2 2018 and held it in 1 quarter. The position peaked at $1.36K in Q2 2018. 115 funds tracked by Wall St. Rank hold ATRA as of Q3 2018.

  • Rehmann Capital Advisory Group reported no remaining Atara Biotherapeutics position as of Q3 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 1 Atara Biotherapeutics share in Q3 2018, an estimated $1.36K.
  • Rehmann Capital Advisory Group first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's Atara Biotherapeutics position peaked at $1.36K in Q2 2018.
  • 115 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2018, filed 20 Nov 2018.